Pharmacies have both the legal authority and, in some circumstances, the legal obligation to decline and report prescriptions they determine are suspicious. The practitioner who assumes that every prescription they issue will be filled without pharmacist scrutiny is a practitioner who does not understand the regulatory framework within which the pharmacy operates.
The Pharmacist’s Corresponding Responsibility
Federal regulations at 21 C.F.R. 1306.04 provide that a prescription for a controlled substance to be effective must be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of professional practice, and that an order not issued in the usual course of professional medical treatment is not a prescription within the meaning of the Act. The person knowingly filling such a purported prescription is subject to the penalties provided for violations of the controlled substances laws.
This corresponding responsibility is the legal basis for the DEA’s enforcement actions against pharmacists and pharmacies that filled prescriptions from known pill mills without exercising professional judgment about their legitimacy.
Suspicious Order Reporting Requirements
DEA regulations at 21 C.F.R. 1301.74 require DEA registrants, including pharmacies, to design and operate a system to disclose suspicious orders of controlled substances and to inform the DEA Division Office of suspicious orders when discovered. A suspicious order includes orders of unusual size, orders deviating substantially from a normal pattern, and orders of unusual frequency. The suspicious order reporting requirement has been interpreted to apply primarily to pharmacies’ acquisition of controlled substances from distributors, and the DEA’s enforcement of suspicious order reporting has been concentrated at the distributor level.
State Law Reporting Requirements
Many states have enacted reporting requirements for pharmacists who identify potentially fraudulent prescriptions or controlled substance diversion. These requirements vary by state and may include mandatory reporting to the state pharmacy board, the state PDMP administrator, or local law enforcement when a pharmacist declines to fill a prescription on suspicion of fraud.
Need Help With Your Case?
Don't face criminal charges alone. Our experienced defense attorneys are ready to fight for your rights and freedom.
- 100% Confidential
- Response Within 1 Hour
- No Obligation Consultation
Or call us directly:
(212) 300-5196A pharmacist who declines to fill a practitioner’s prescription and reports the declination to the state pharmacy board or the DEA has potentially initiated an investigation of the practitioner. That report becomes part of the regulatory record that the DEA accesses through its coordination with state pharmacy boards. A pattern of declined prescriptions from a single practitioner provides investigative evidence of prescribing outside the usual course of professional practice without requiring the DEA to conduct independent prescribing analysis.
The pharmacist who declines to fill a prescription and makes a report is exercising professional judgment that the regulatory framework specifically encourages. The practitioner whose prescriptions are the subject of those reports is a practitioner whose prescribing is being documented by professional peers as inconsistent with legitimate medical practice. That documentation reaches the DEA and the state medical board.
Todd Spodek
Lead Attorney & Founder
Featured on Netflix's "Inventing Anna," Todd Spodek brings decades of high-stakes criminal defense experience. His aggressive approach has secured dismissals and acquittals in cases others deemed unwinnable.
Practical Implications for Prescribers
Prescribers whose controlled substance prescriptions are frequently declined by pharmacies should treat those declinations as significant clinical and legal signals. A pharmacy that declines to fill a prescription is communicating a professional judgment that the prescription is not within the scope of legitimate medical practice as the pharmacist understands it. The pattern of declined prescriptions is itself evidence that the prescribing is anomalous relative to what the pharmacy community regards as standard practice.

A federal agent calls you and says they "just want to ask a few questions" about a business transaction.
Is it safe to talk to them informally?
There is no such thing as an informal conversation with a federal agent. Under 18 U.S.C. 1001, making any false statement to a federal agent is a felony, even without being under oath. Always consult an attorney before speaking with investigators.
This is general information only. Contact us for advice specific to your situation.
The prescriber who receives feedback from pharmacies about specific prescriptions, and who takes that feedback seriously by reviewing the clinical basis for the prescriptions in question, is responding to a professional signal that reflects genuine commitment to legitimate practice. The prescriber who dismisses pharmacy concerns and continues prescribing in the same manner is creating a record of awareness and non-response that, in a subsequent investigation, will be characterized as indifference to known compliance problems.